A Phase 1, Multi-Cohort, Single Dose Study to Assess The Relative Bioavailability, Performance, and Safety of Two Novel Formulations of CRN00808
Latest Information Update: 10 Jul 2021
At a glance
- Drugs Paltusotine (Primary) ; Paltusotine (Primary) ; Lansoprazole
- Indications Acromegaly
- Focus Pharmacokinetics
- Sponsors Crinetics Pharmaceuticals
Most Recent Events
- 05 Jul 2021 Planned number of patients changed from 48 to 60.
- 05 Jul 2021 Status changed from recruiting to completed.
- 23 Mar 2021 Trial design and dose proportionality for cohorts 1-4 presented at the 103rd Annual Meeting of the Endocrine Society